{"entity":{"id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of BI1206 in advanced solid tumours, run by BioInvent International AB, now recruiting.","summary":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04219254 by BioInvent International AB, with 197 participants planned, started 2020-06-29 and due to reach its primary completion in 2027-11. Interventions recorded: BI1206.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04219254","url":"https://clinicaltrials.gov/study/NCT04219254"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["bioinvent-international","merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04219254","phase":"1/2","setting":"A Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","sponsor":"BioInvent International AB","enrolled":197,"outcomes":[]},"route":"/trials/nct04219254/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}